Anvisa tightens regulations on weight-loss drug Mounjaro in Brazil

A new weight-loss drug, Mounjaro, is now available in Brazilian pharmacies, prompting stricter regulations from the National Health Surveillance Agency (Anvisa). The agency aims to curb misuse and ensure responsible use of the medication. Mounjaro, initially for type 2 diabetes, joins Ozempic and Wegovy as injectable weight-loss drugs. Anvisa will require prescription retention for these GLP-1 analog medications to prevent unauthorized use and combat potential smuggling. The new regulations follow concerns about the drugs' use without medical guidance and potential side effects. Anvisa will monitor pharmacies to control access, while the possibility of inclusion in the public health system remains under discussion.